{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:35:52Z","timestamp":1788816952220,"version":"build-2803163510"},"reference-count":95,"publisher":"Society of Nuclear Medicine","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2967\/jnumed.121.263201","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:11:10Z","timestamp":1654085470000},"page":"60S-67S","source":"Crossref","is-referenced-by-count":101,"title":["Imaging of Synaptic Density in Neurodegenerative Disorders"],"prefix":"10.2967","volume":"63","author":[{"given":"Richard E.","family":"Carson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Naganawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Toyonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Koohsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Matuskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd J.","family":"Finnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2022060616200895000_63.Supplement_1.60S.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1519064"},{"key":"2022060616200895000_63.Supplement_1.60S.2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.100.4.1284"},{"key":"2022060616200895000_63.Supplement_1.60S.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1989.tb09190.x"},{"key":"2022060616200895000_63.Supplement_1.60S.4","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00259.2010"},{"key":"2022060616200895000_63.Supplement_1.60S.5","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.12360"},{"key":"2022060616200895000_63.Supplement_1.60S.6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fnmol.2017.00148","article-title":"Puzzling out synaptic vesicle 2 family members functions","volume":"10","author":"Bartholome","year":"2017","journal-title":"Front Mol Neurosci."},{"key":"2022060616200895000_63.Supplement_1.60S.7","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.14-09-05223.1994"},{"key":"2022060616200895000_63.Supplement_1.60S.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00370-X"},{"key":"2022060616200895000_63.Supplement_1.60S.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.6.2150"},{"key":"2022060616200895000_63.Supplement_1.60S.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"2022060616200895000_63.Supplement_1.60S.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.02.022"},{"key":"2022060616200895000_63.Supplement_1.60S.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.04.064"},{"key":"2022060616200895000_63.Supplement_1.60S.13","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin Pharmacol."},{"key":"2022060616200895000_63.Supplement_1.60S.14","doi-asserted-by":"publisher","DOI":"10.1021\/ml500285t"},{"key":"2022060616200895000_63.Supplement_1.60S.15","doi-asserted-by":"crossref","first-page":"1700003","DOI":"10.1002\/ardp.201700003","article-title":"Interaction of approved drugs with synaptic vesicle protein 2A","volume":"350","author":"Danish","year":"2017","journal-title":"Arch Pharm (Weinheim)."},{"key":"2022060616200895000_63.Supplement_1.60S.16","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300482"},{"key":"2022060616200895000_63.Supplement_1.60S.17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ddtec.2017.11.003","article-title":"Discovery and development of SV2A PET tracers: potential for imaging synaptic density and clinical applications","volume":"25","author":"Mercier","year":"2017","journal-title":"Drug Discov Today Technol."},{"key":"2022060616200895000_63.Supplement_1.60S.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2016.03.004"},{"key":"2022060616200895000_63.Supplement_1.60S.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.136143"},{"key":"2022060616200895000_63.Supplement_1.60S.20","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/acs.molpharmaceut.7b00235","article-title":"Pharmacokinetic characterization of [18F]UCB-H PET radiopharmaceutical in the rat brain","volume":"14","author":"Becker","year":"2017","journal-title":"Mol Pharm."},{"key":"2022060616200895000_63.Supplement_1.60S.21","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00905"},{"key":"2022060616200895000_63.Supplement_1.60S.22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2191-219X-3-35","article-title":"Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H","volume":"3","author":"Bretin","year":"2013","journal-title":"EJNMMI Res."},{"key":"2022060616200895000_63.Supplement_1.60S.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.168179"},{"key":"2022060616200895000_63.Supplement_1.60S.24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6667"},{"key":"2022060616200895000_63.Supplement_1.60S.25","first-page":"631","article-title":"Tracer kinetic analysis of the SV2A ligand 11C-UCBA as a PET marker for synaptic density in humans [abstract]","volume":"58","author":"Lubberink","year":"2017","journal-title":"J Nucl Med."},{"key":"2022060616200895000_63.Supplement_1.60S.26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.trci.2017.08.004","article-title":"Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18F]UCB-H","volume":"3","author":"Bahri","year":"2017","journal-title":"Alzheimers Dement (N Y)."},{"key":"2022060616200895000_63.Supplement_1.60S.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04357-w"},{"key":"2022060616200895000_63.Supplement_1.60S.28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acschemneuro.8b00526","article-title":"Synthesis and in\u00a0vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates","volume":"10","author":"Li","year":"2019","journal-title":"ACS Chem Neurosci."},{"key":"2022060616200895000_63.Supplement_1.60S.29","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-018-1260-5"},{"key":"2022060616200895000_63.Supplement_1.60S.30","doi-asserted-by":"crossref","unstructured":"Cai Z Li S Zhang W . Synthesis and preclinical evaluation of an 18F-labeled synaptic vesicle glycoprotein 2A PET imaging probe: [18F]SynVesT-2. ACS Chem Neurosci. 2020;11:592\u2013603.","DOI":"10.1021\/acschemneuro.9b00618"},{"key":"2022060616200895000_63.Supplement_1.60S.31","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00259-020-05149-3","article-title":"Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A","volume":"48","author":"Li","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022060616200895000_63.Supplement_1.60S.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.249144"},{"key":"2022060616200895000_63.Supplement_1.60S.33","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.96.5.1355"},{"key":"2022060616200895000_63.Supplement_1.60S.34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.4.2130"},{"key":"2022060616200895000_63.Supplement_1.60S.35","doi-asserted-by":"publisher","DOI":"10.1177\/38.6.2110586"},{"key":"2022060616200895000_63.Supplement_1.60S.36","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3805-10.2011"},{"key":"2022060616200895000_63.Supplement_1.60S.37","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1177\/0271678X17724947","article-title":"Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans","volume":"38","author":"Finnema","year":"2018","journal-title":"J Cereb Blood Flow Metab."},{"key":"2022060616200895000_63.Supplement_1.60S.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4119-8"},{"key":"2022060616200895000_63.Supplement_1.60S.39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.228080"},{"key":"2022060616200895000_63.Supplement_1.60S.40","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/0271678X20946198","article-title":"Binding of the synaptic vesicle radiotracer [11C]UCB-J is unchanged during functional brain activation using a visual stimulation task","volume":"41","author":"Smart","year":"2021","journal-title":"J Cereb Blood Flow Metab."},{"key":"2022060616200895000_63.Supplement_1.60S.41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/epi.14701","article-title":"A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers","volume":"60","author":"Finnema","year":"2019","journal-title":"Epilepsia."},{"key":"2022060616200895000_63.Supplement_1.60S.42","doi-asserted-by":"crossref","first-page":"e22157","DOI":"10.1002\/syn.22157","article-title":"Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain","volume":"74","author":"Varn\u00e4s","year":"2020","journal-title":"Synapse."},{"key":"2022060616200895000_63.Supplement_1.60S.43","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1177\/0271678X19879230","article-title":"Assessment of a white matter reference region for 11C-UCB-J PET quantification","volume":"40","author":"Rossano","year":"2020","journal-title":"J Cereb Blood Flow Metab."},{"key":"2022060616200895000_63.Supplement_1.60S.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09562-7"},{"key":"2022060616200895000_63.Supplement_1.60S.45","doi-asserted-by":"crossref","unstructured":"Angarita GA Worhunsky PD Naganawa M . Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: an exploratory 11C-UCB-J positron emission tomography study in humans. Addict Biol. December 1, 2021 [Epub ahead of print].","DOI":"10.1111\/adb.13123"},{"key":"2022060616200895000_63.Supplement_1.60S.46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11307-019-01387-6","article-title":"Validation of parametric methods for [11C]UCB-J PET imaging using subcortical white matter as reference tissue","volume":"22","author":"Mertens","year":"2020","journal-title":"Mol Imaging Biol."},{"key":"2022060616200895000_63.Supplement_1.60S.47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243949"},{"key":"2022060616200895000_63.Supplement_1.60S.48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223867"},{"key":"2022060616200895000_63.Supplement_1.60S.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118302"},{"key":"2022060616200895000_63.Supplement_1.60S.50","unstructured":"Bertoglio D Verhaeghe J Wyffels L . Synaptic vesicle glycoprotein 2A is affected in the CNS of Huntington\u2019s disease mice and post-mortem human HD brain. J Nucl Med. September 16, 2021 [Epub ahead of print]."},{"key":"2022060616200895000_63.Supplement_1.60S.51","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X20931140"},{"key":"2022060616200895000_63.Supplement_1.60S.52","doi-asserted-by":"crossref","first-page":"715811","DOI":"10.3389\/fnsyn.2021.715811","article-title":"Synaptic density and neuronal metabolic function measured by positron emission tomography in the unilateral 6-OHDA rat model of Parkinson\u2019s disease","volume":"13","author":"Raval","year":"2021","journal-title":"Front Synaptic Neurosci."},{"key":"2022060616200895000_63.Supplement_1.60S.53","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-0932-8_24"},{"key":"2022060616200895000_63.Supplement_1.60S.54","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23795"},{"key":"2022060616200895000_63.Supplement_1.60S.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2013.07.011"},{"key":"2022060616200895000_63.Supplement_1.60S.56","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25682"},{"key":"2022060616200895000_63.Supplement_1.60S.57","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28064"},{"key":"2022060616200895000_63.Supplement_1.60S.58","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/mds.28216","article-title":"Loss of presynaptic terminal integrity in the substantia nigra in early Parkinson\u2019s disease","volume":"35","author":"Delva","year":"2020","journal-title":"Mov Disord."},{"key":"2022060616200895000_63.Supplement_1.60S.59","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004058"},{"key":"2022060616200895000_63.Supplement_1.60S.60","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/mds.28617","article-title":"Reduced synaptic density in patients with Lewy body dementia: An [11C]UCB-J PET imaging study","volume":"36","author":"Andersen","year":"2021","journal-title":"Mov Disord."},{"key":"2022060616200895000_63.Supplement_1.60S.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.01.015"},{"key":"2022060616200895000_63.Supplement_1.60S.62","doi-asserted-by":"publisher","DOI":"10.1126\/science.1074069"},{"key":"2022060616200895000_63.Supplement_1.60S.63","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270502"},{"key":"2022060616200895000_63.Supplement_1.60S.64","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu190"},{"key":"2022060616200895000_63.Supplement_1.60S.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2022060616200895000_63.Supplement_1.60S.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2009.07.002"},{"key":"2022060616200895000_63.Supplement_1.60S.67","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.150045"},{"key":"2022060616200895000_63.Supplement_1.60S.68","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828f17de"},{"key":"2022060616200895000_63.Supplement_1.60S.69","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"key":"2022060616200895000_63.Supplement_1.60S.70","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e318232a379"},{"key":"2022060616200895000_63.Supplement_1.60S.71","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04461-x"},{"key":"2022060616200895000_63.Supplement_1.60S.72","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/alz.12097","article-title":"In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET","volume":"16","author":"Mecca","year":"2020","journal-title":"Alzheimers Dement."},{"key":"2022060616200895000_63.Supplement_1.60S.73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jalz.2015.12.005","article-title":"Meta-analysis of synaptic pathology in Alzheimer\u2019s disease reveals selective molecular vesicular machinery vulnerability","volume":"12","author":"de Wilde","year":"2016","journal-title":"Alzheimers Dement."},{"key":"2022060616200895000_63.Supplement_1.60S.74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13195-020-00742-y","article-title":"Association of A\u03b2 deposition and regional synaptic density in early Alzheimer\u2019s disease: a PET imaging study with [11C]UCB-J","volume":"13","author":"O\u2019Dell","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"2022060616200895000_63.Supplement_1.60S.75","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1212\/WNL.0000000000009818","article-title":"In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment","volume":"95","author":"Vanhaute","year":"2020","journal-title":"Neurology."},{"key":"2022060616200895000_63.Supplement_1.60S.76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-021-00772-0","article-title":"In vivo tau pathology is associated with synaptic loss and altered synaptic function","volume":"13","author":"Coomans","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"2022060616200895000_63.Supplement_1.60S.77","doi-asserted-by":"crossref","unstructured":"Mecca AP Chen M-K O\u2019Dell RS . Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer\u2019s disease. Neurobiol Aging. 2022;111:44\u201353.","DOI":"10.1016\/j.neurobiolaging.2021.11.004"},{"key":"2022060616200895000_63.Supplement_1.60S.78","doi-asserted-by":"crossref","unstructured":"Chen MK Mecca AP Naganawa M . Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer\u2019s disease: a tracer kinetic modeling study. J Cereb Blood Flow Metab. 2021:271678X211004312.","DOI":"10.1177\/0271678X211004312"},{"key":"2022060616200895000_63.Supplement_1.60S.79","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.11.1803"},{"key":"2022060616200895000_63.Supplement_1.60S.80","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-015-0013-z"},{"key":"2022060616200895000_63.Supplement_1.60S.81","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acn3.51407","article-title":"Synaptic density in carriers of C9orf72 mutations: a [11C]UCB-J PET study","volume":"8","author":"Malpetti","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"2022060616200895000_63.Supplement_1.60S.82","doi-asserted-by":"crossref","first-page":"16092","DOI":"10.1038\/s41598-021-95499-1","article-title":"In vivo exploration of synaptic projections in frontotemporal dementia","volume":"11","author":"Salmon","year":"2021","journal-title":"Sci Rep."},{"key":"2022060616200895000_63.Supplement_1.60S.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2012.05.043"},{"key":"2022060616200895000_63.Supplement_1.60S.84","first-page":"938530","article-title":"Differential changes in postsynaptic density proteins in postmortem Huntington\u2019s disease and Parkinson\u2019s disease human brains","volume":"2014","author":"Fourie","year":"2014","journal-title":"J Neurodegener Dis."},{"key":"2022060616200895000_63.Supplement_1.60S.85","doi-asserted-by":"crossref","unstructured":"Delva A Michiels L Koole M Van Laere K Vandenberghe W . Synaptic damage and its clinical correlates in people with early Huntington disease: a PET study. Neurology. 2022;98:e83\u2013e94.","DOI":"10.1212\/WNL.0000000000012969"},{"key":"2022060616200895000_63.Supplement_1.60S.86","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25872"},{"key":"2022060616200895000_63.Supplement_1.60S.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.04.047"},{"key":"2022060616200895000_63.Supplement_1.60S.88","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jnen\/60.5.403","article-title":"Cortical synapse loss in progressive supranuclear palsy","volume":"60","author":"Bigio","year":"2001","journal-title":"J Neuropathol Exp Neurol."},{"key":"2022060616200895000_63.Supplement_1.60S.89","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/mds.28188","article-title":"Synaptic loss in primary tauopathies revealed by [11C]UCB-J positron emission tomography","volume":"35","author":"Holland","year":"2020","journal-title":"Mov Disord."},{"key":"2022060616200895000_63.Supplement_1.60S.90","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/epi.16653","article-title":"Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB-J positron emission tomography study","volume":"61","author":"Finnema","year":"2020","journal-title":"Epilepsia."},{"key":"2022060616200895000_63.Supplement_1.60S.91","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41398-021-01515-3","article-title":"The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study","volume":"11","author":"Onwordi","year":"2021","journal-title":"Transl Psychiatry."},{"key":"2022060616200895000_63.Supplement_1.60S.92","doi-asserted-by":"crossref","unstructured":"Radhakrishnan R Skosnik PD Ranganathan M . In vivo evidence of lower synaptic vesicle density in schizophrenia. Mol Psychiatry. June 16, 2021 [Epub ahead of print].","DOI":"10.1038\/s41380-021-01184-0"},{"key":"2022060616200895000_63.Supplement_1.60S.93","doi-asserted-by":"crossref","unstructured":"Michiels L Mertens N Thijs L . Changes in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET\/MR study. J Cereb Blood Flow Metab. 2021:271678X211047759.","DOI":"10.1177\/0271678X211047759"},{"key":"2022060616200895000_63.Supplement_1.60S.94","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1038\/s41380-020-00891-4","article-title":"Preliminary in\u00a0vivo evidence of lower hippocampal synaptic density in cannabis use disorder","volume":"26","author":"D\u2019Souza","year":"2021","journal-title":"Mol Psychiatry."},{"key":"2022060616200895000_63.Supplement_1.60S.95","doi-asserted-by":"crossref","first-page":"117877","DOI":"10.1016\/j.neuroimage.2021.117877","article-title":"Synaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study","volume":"232","author":"Michiels","year":"2021","journal-title":"Neuroimage."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.263201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T19:21:33Z","timestamp":1654543293000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.263201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":95,"journal-issue":{"issue":"Supplement 1","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2967\/jnumed.121.263201"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.263201","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}